LY364947

Suppliers

Names

[ Name ]:
LY364947

[Synonym ]:
4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]quinoline
Quinoline, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline
LY 364947
4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]quinoline
LY364947
LY-364947

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
490.8±45.0 °C at 760 mmHg

[ Molecular Formula ]:
C₁₇H₁₂N₄

[ Molecular Weight ]:
272.304

[ Flash Point ]:
268.7±15.1 °C

[ Exact Mass ]:
272.106201

[ PSA ]:
54.46000

[ LogP ]:
2.35

[ Appearance of Characters ]:
white to beige

[ Vapour Pressure ]:
0.0±1.2 mmHg at 25°C

[ Index of Refraction ]:
1.700

[ Storage condition ]:
Store at RT

[ Water Solubility ]:
DMSO: soluble2mg/mL, clear

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS06, GHS09

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301-H315-H319-H335-H400

[ Precautionary Statements ]:
P261-P273-P301 + P310-P305 + P351 + P338

[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ Hazard Codes ]:
T,N

[ Risk Phrases ]:
25-36/37/38-50/53

[ Safety Phrases ]:
26-45-60-61

[ RIDADR ]:
UN 2811 6.1/PG 3

[ HS Code ]:
2933990090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2933990090

[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

J. Med. Chem. 46 , 3953-3956, (2003)

Pyrazole-based inhibitors of the transforming growth factor-beta type I receptor kinase domain (TbetaR-I) are described. Examination of the SAR in both enzyme- and cell-based in vitro assays resulted ...

Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.

J. Med. Chem. 49 , 2138-2142, (2006)

Novel dihydropyrrolopyrazole-substituted benzimidazoles were synthesized and evaluated in vitro as inhibitors of transforming growth factor-beta type I receptor (TGF-beta RI), TGF-beta RII, and mixed ...

Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

Bioorg. Med. Chem. Lett. 13 , 4355-4359, (2003)

We describe the discovery, using shape-based virtual screening, of a potent, ATP site-directed inhibitor of the TbetaRI kinase, an important and novel drug target for fibrosis and cancer. The first de...